Significance of antinuclear antibody in Indian patients with rheumatoid arthritis
Abstract
This study aimed to understand the differences in disease duration, serological parameters, extra Articular Manifestation and treatment of Indian RA patients depending upon antinuclear antibody (ANA) positivity. This study was planned as a cross-sectional observational study, wherein 184 patients 18 years and above diagnosed as RA and tested for Antinuclear Antibody, who reported for consultation at rheumatology department of Medanta –The Medicity hospital from August 2020 to February 2022 were enrolled in this study. Patient’s demographic data, present complains, extra –articular features, seronegative features, associated medical conditions like CAD, HTN, DM, Tuberculosis, hypothyroidism etc, family history current and previous was collected on the day of consultation with physician. Cross tables were generated and Chi square test was used for testing of association for comparison between groups. The study included 184 patients of RA. ANA positivity rate was 45.1% (n=83). The majority of the patients were female- 155(84.2%). There was no significant association was observed between the study groups in terms of gender, mean age, mean age of onset, and median disease duration.
Downloads
References
Aitcheson CT, Peebles C, Joslin F, et al. Characteristics of antinuclear antibodies in rheumatoid arthritis. Arthritis Rheum. 1980;23(5):528–538. [PubMed] [Google Scholar]
Al-Osami MH, Allawi AAM, Al-Saadawi TH. The association of smoking with the extra-articular manifestations in rheumatoid arthritis patients. Postgrad Med J. 2013;12(1):146–152. [Google Scholar]
Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003; 349:1526–1533. [PubMed: 14561795]
Dinse GE, Parks CG, Weinberg CR, Co CA, Wilkerson J, Zeldin DC, et al. Increasing prevalence of antinuclear antibodies in the United States. Arthritis Rheumatol 2020;72:1026–35.
Fernandez SAV, Lobo AZC, Oliveira ZNP, et al. Prevalence of antinuclear autoantibodies in the serum of normal blood donors. Rev HospClin. 2003;58(6):315–319. [PubMed] [Google Scholar]
https://pubmed.ncbi.nlm.nih.gov/15899041/
https://pubmed.ncbi.nlm.nih.gov/24854356/
https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Antinuclear-Antibodies-ANA
Khidoyatova, M. R., Kayumov, U. K., Inoyatova, F. K., Fozilov, K. G., Khamidullaeva, G. A., & Eshpulatov, A. S. (2022). Clinical status of patients with coronary artery disease post COVID-19. International Journal of Health & Medical Sciences, 5(1), 137-144. https://doi.org/10.21744/ijhms.v5n1.1858
Li Q-Z, Karp DR, Quan J, Branch VK, Zhou J, Lian Y, et al. Risk factors for ANA positivity in healthy persons. Arthritis Res Ther2011;13:R38.
Nishimura S, Nishiya K, Hisakawa N, Chikazawa H, Ookubo S, Nakatani K, Hashimoto K. Positivity for antinuclear antibody in patients with advanced rheumatoid arthritis. Acta Med Okayama. 1996 Oct;50(5):261-5. doi: 10.18926/AMO/30501. PMID: 8914679.
Racoubian E, Zubaid RM, Shareefd MA, et al. Prevalence of antinuclear antibodies in healthy Lebanese subjects, 2008-2015: a cross-sectional study involving 10 814 subjects. Rheumatol Int. 2016;36(9):1231–1236. [PubMed] [Google Scholar]
Ratnawati, I. G. A. A., Suandayani, N. K. T., & Sutapa, G. N. (2019). The linearity of x-ray devices radiation output and its relationship with patient thickness. International Journal of Physical Sciences and Engineering, 3(3), 1–6. https://doi.org/10.29332/ijpse.v3n3.351
Solow EB, Vongpatanasin W, Skaug B, Karp DR, Ayers C, de Lemos JA. Antinuclear antibodies are associated with all-cause Mortality and cardiovascular outcomes in the general population. J Am CollCardiol 2015;65:2669–70.
Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Health and treatment of diabetes mellitus. International Journal of Health Sciences, 5(1), i-v. https://doi.org/10.53730/ijhs.v5n1.2864
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
